stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Net margin
HUTCHMED (China) Limited Sponsored ADR's net margin over the twelve months to 30 June 2023 was −23.6%. Over the past ten years it has ranged from −84.6% (fiscal 2022) to 83.3% (fiscal 2025) — the current reading is the highest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of −2.45% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 83.3% | 77.31 |
| FY2024 | 5.99% | (6.04) |
| FY2023 | 12.0% | 96.65 |
| FY2022 | −84.6% | (29.96) |
| FY2021 | −54.7% | 0.49 |
| FY2020 | −55.2% | (3.40) |
| FY2019 | −51.8% | (16.81) |
| FY2018 | −34.9% | (23.86) |
| FY2017 | −11.1% | (16.49) |
| FY2016 | 5.41% | 25.06 |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2023 | 31.6% | 119.86 |
| Dec 2022 | −88.2% | (7.58) |
| Jun 2022 | −80.7% | 0.15 |
| Jun 2021 | −80.8% | (30.35) |
| 10 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | 13.3% |
| ANIP ANI Pharmaceuticals, Inc. compare | 11.2% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −1.76% |
| HCM HUTCHMED (China) Limited Sponsored ADR | −23.6% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −37.4% |
| TRLV Trulieve Cannabis Corp. compare | −41.2% |
| PRGO Perrigo Company plc compare | −43.3% |
| ALVO Alvotech compare | −101.1% |
| Drug Manufacturers Specialty & Generic industry median | −2.45% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement